Advertisement

Topics

Ocugen to advance pipeline with $7.5 million in Series B financing

14:00 EDT 16 Jun 2017 | Healio

Ocugen has closed a $7.5 million round of Series B funding to support the advancement of potential sight-saving ophthalmology products into clinical trials, the company announced in a press release. Led by the Turkish pharmaceutical company Abdi Ibrahim and the JSC Lancaster Group from Kazakhstan, investors also included Frank Leo and John Zhang, PhD.

Original Article: Ocugen to advance pipeline with $7.5 million in Series B financing

NEXT ARTICLE

More From BioPortfolio on "Ocugen to advance pipeline with $7.5 million in Series B financing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...